SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational Phase III clinical trials of its lead product candidate, the ...
SpyGlass Pharma has randomized the first patients in its 2 registrational phase 3 clinical trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) for the lowering of intraocular pressure (IOP) ...
The ongoing BIM revolution is transforming how buildings are constructed. And that’s true at every level, from the initial architectural drawings right down to the design and fabrication of metal ...
42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or ...
Despite all the buzz around building information modeling, it is really a reintroduction of traditional practices, with technology added. Throughout the history of architecture, scale models have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback